EMERYVILLE, Calif., Dec. 01, 2016 -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it has executed with its long-time partner Kuraray Co., LTD (TYO:3405) a multi-year extension to their collaboration agreement for the use of Amyris’s Biofene® branded ß-Farnesene in liquid farnesene rubber (“LFR”) and farnesene-based elastomer applications. This collaboration, which originally began in 2011, features increased farnesene supply to Kuraray and joint marketing of products to industry and end-customers.
Amyris’s sugar cane-derived Biofene forms the basis for a wide range of products varying from specialty products such as cosmetics, perfumes, detergents and industrial lubricants, to transportation fuels such as diesel and jet fuel. As a tailor made pure hydrocarbon it provides numerous advantages when compared to petroleum-based oils and chemicals and is renewable, contributing to a sustainable future.
Farnesene Fueling Better Products Across the World – Including Tires
Kuraray’s recent technological successes with rubber containing farnesene includes an enhanced synthetic additive for tire manufacturers. Its novel LFR and other farnesene- containing rubber materials add substantial grip and cornering capability to tires, particularly in cold, snow and ice conditions. In addition, its hydrogenated styrenic-farnesene copolymer (“HSFC”) has demonstrated superior shock absorption in products ranging from footwear to specialty construction materials.
“We are delighted to extend our relationship with Kuraray,” said John Melo, CEO of Amyris. “Introducing a novel molecule to industry requires patience and creativity. However, Kuraray’s technical expertise and customer relationships have reached the point where their products are now becoming mainstream and this, in turn, is fueling further broadening market adoption of our farnesene for a variety of products.”
“Kuraray has many years’ experience working with farnesene, which we believe has many end-market applications,” said Mr. Kenichi Abe, President of Kuraray’s Isoprene business. “Our collaboration with Amyris and their breakthrough-ability to produce farnesene at industrial scale, and at competitive price, enables Kuraray to provide its customers products with superior performance and that are renewably sourced.”
About Amyris
Amyris is the integrated renewable products company that is enabling the world's leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise® products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, and pharmaceuticals and nutraceuticals. More information about the company is available at www.amyris.com.
Forward-Looking Statements
This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as market adoption of farnesene) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to manufacturing capacity at Amyris’s Brotas facility, delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris’s reliance on third parties to achieve its goals, and other risks detailed in the “Risk Factors” section of Amyris’s quarterly report on Form 10-Q filed on November 9, 2016. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.
Amyris, the Amyris logo and Biofene are registered trademarks of Amyris, Inc. All other trademarks are trademarks of their respective owners.
Contact: Peter DeNardo Director, Investor Relations and Corporate Communications Amyris, Inc. +1 (510) 740-7481 [email protected] [email protected]


Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 



